Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17589035 | 0.81 | PDCD1LG2 (0.38) | CD274KCNH2CYP2D6TYRO3DYRK1B | |
| SCHEMBL22179001 | 0.79 | KMT2A (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4579208 | 0.77 | NOS3 (0.36) | CSNK1A1CLK4TYRO3DYRK1B | |
| SCHEMBL30238970 | 0.77 | NOS3 (0.36) | CSNK1A1CLK4TYRO3DYRK1B | |
| SCHEMBL16071417 | 0.74 | ALDH1A1 (0.42) | SLC6A4PDCD1CD274KCNH2CYP2D6 | |
| SCHEMBL4321200 | 0.74 | KMT2A (0.39) | CSNK1A1CLK4TYRO3DYRK1B | |
| SCHEMBL24046195 | 0.73 | KDM4E (0.32) | — | |
| SCHEMBL6219173 | 0.73 | AURKA (0.34) | — | |
| SCHEMBL21479325 | 0.73 | L3MBTL1 (0.37) | — | |
| SCHEMBL23152791 | 0.73 | MAOB (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2020-05-07 | — | — | US | disclosed |
| CN-110769830-A | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | 马瓦隆治疗有限公司 | 2020-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | SLC6A4 562/4885SLC6A2 989/4885SLC6A3 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.